Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- Rhagargraffiad › Ymchwil
- Cyhoeddwyd
The costs and cost-effectiveness of different service models of palliatice care, focusing on end of life care: A rapid review
Spencer, L., Anthony, B., Davies, J., Pisavadia, K., Gillen, E., Noyes, J., Fitzsimmons, D., Lewis, R., Cooper, A., Hughes, D., Edwards, R. T. & Edwards, A., 7 Maw 2024, MedRxiv, 118 t.Allbwn ymchwil: Papur gweithio › Rhagargraffiad
- Cyhoeddwyd
What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review
Spencer, L., Hendry, A., Makanjuola, A., Anthony, B., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 28 Ion 2023, 34 t. (MedRxiv).Allbwn ymchwil: Papur gweithio › Rhagargraffiad
- Cyhoeddwyd
What is the long-term impact of COVID-19 on the Health-Related Quality of Life of individuals with mild symptoms (or non-hospitalised): A rapid review
Spencer, L., Hendry, A., Makanjuola, A., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 9 Medi 2022, Health and Care Research Wales, 47 t.Allbwn ymchwil: Papur gweithio › Rhagargraffiad
- Erthygl adolygu › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
A Systematic Review of Economic Evaluations of Advanced Therapy Medicinal Products
Lloyd Williams, H. & Hughes, D., Meh 2021, Yn: British Journal of Clinical Pharmacology. 87, 6, t. 2428-2443 16 t.Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
- Cyhoeddwyd
Evidence to support inclusion of pharmacogenetic biomarkers in randomised controlled trials
Johnson, D., Jorgensen, A., Hughes, D. & Pirmohamed, M., 1 Medi 2019, Yn: Journal of Personalized Medicine. 9, 3, 19 t., 42.Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
- Safe Gwe / Cyhoeddiad Gwe › Ymchwil
- Cyhoeddwyd
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe
- Adoddiad Arall › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff? Report number: RR_00018 (November 2021)
Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 1 Tach 2021, 36 t.Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall › adolygiad gan gymheiriaid
- Adoddiad Arall › Ymchwil › Heb ei adolygu gan gymheiriaid
- Cyhoeddwyd
RES00019. Wales COVID-19 Evidence Centre. A rapid evidence summary indicating the evidence of the inverse care law in social care in Wales and has this been exacerbated by the COVID-19 pandemic?
Spencer, L., Hendry, A., Makanjuola, A., Hughes, D., Wilkinson, C., Pisavadia, K., Davies, J., Fitzsimmons, D. & Edwards, R. T., Chwef 2022, Welsh Government. 33 t.Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall
- Cyhoeddwyd
RES00038. Wales COVID-19 Evidence Centre. A rapid evidence summary of the cost impact of Long COVID on employment and caring responsibilities
Spencer, L., Hendry, A., Davies, J., Pisavadia, K., Hughes, D. & Edwards, R. T., Mai 2022, Welsh Government. 18 t.Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall
- Adroddiad Comisiwn › Ymchwil › Adolygwyd gan gymheiriaid
- Cyhoeddwyd
What innovations can address inequalities experienced by women and girls due to the COVID-19 pandemic across the different areas of life/domains: work, health, living standards, personal security, participation and education? Report number – RR00027 (January 2022). Gender Inequalities: COVID-19 initiatives
Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Pisavadia, K., Davies, J., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 15 Ion 2022, Health and Care Research Wales.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn › adolygiad gan gymheiriaid
- Adroddiad Comisiwn › Ymchwil › Heb ei adolygu gan gymheiriaid
- Cyhoeddwyd
A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.
Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
AWMSG criteria for appraising new medicines.
Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn